DSIP
Neuromodulatory nonapeptide
Also Delta sleep-inducing peptide, Delta sleep inducing peptide, Emideltide, DSIP peptide, Deltaran
- Evidence
- CAnimal and cell studies
- FDA status
- Not approvedas of 2026-10-26
- Route
- Injection
- Studies cited
- 4 human1 animal or cell
Sold for
DSIP is sold as a natural sleep peptide that deepens slow-wave sleep and is also claimed to help with pain and withdrawal.
Studies say
Small, old human studies with mixed results and no modern trial, so the grade is C.
Why grade C. For sleep, the use DSIP is sold for, the human evidence is a cluster of small studies from the late 1970s and 1980s, mostly from the group that discovered the peptide, plus one later double-blind trial in 16 chronic insomniacs whose authors called the effect weak. There has been no adequately powered trial in the past 30 years, and no study of the injectable products now sold online. 267
FDA. Not approved by the FDA for any use and sold as a research chemical. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted against adding DSIP (reviewed under the name emideltide) to the list of substances pharmacies may compound. 7
Written from 7 cited sources. Last refreshed 2026-10-27. Not physician reviewed.
Evidence checklist
- Randomised controlled trial One double-blind trial, 16 insomniacsyes
- Human study over 100 people Largest controlled study was 16 peopleno
- More than one research group Mostly the discovering group's studiesno
- Clinical outcomes, not surrogate markers Sleep measures only; effect called weakno
- Human safety data beyond case reports Old IV studies; no repeated-use datano
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide first isolated in the 1970s from the blood of rabbits whose brains had been electrically stimulated to produce sleep. The synthetic version was made and compared with the natural isolate in 1977. 1
Despite the name, DSIP's role in normal sleep was never settled. Its gene has not been identified, it is hard to measure reliably in blood, and later work questioned whether it is a sleep hormone at all. It has no approved medical use anywhere. 16
How it works
How DSIP acts is not known. No specific receptor has been identified. Early studies reported that intravenous DSIP increased slow-wave (delta) sleep and shifted sleep architecture for many hours after a dose, and other reports described effects on pain, stress hormones and opioid or alcohol withdrawal, which led the discoverers to describe it as a general 'programming' or stress-modulating peptide, not a hypnotic. 234
What human research shows
The original clinical work came from Schneider-Helmert and Schoenenberger in Switzerland. In insomnia they reported that a short course of intravenous DSIP normalized sleep in most of a small group of chronic insomniacs, and they later reported benefit in small series of patients with chronic pain and with withdrawal states. These were small studies, some open-label, by the group that discovered the peptide. 234
The best-controlled trial came in 1992: a randomized, double-blind study in 16 chronic insomniacs given intravenous DSIP or placebo. Sleep efficiency and sleep latency improved slightly more on DSIP, but the authors judged the effects weak and said part of the difference could be explained by a shift in the placebo group. 6
When the FDA reviewed the compound for compounding in 2026, its staff recommended against it, and the advisory committee rejected it, in large part because no adequately sized modern trial supports a clinical use. 7
| Study | Model | Finding |
|---|---|---|
| Synthesis and comparison 1977 | Laboratory synthesis compared with the rabbit-derived isolate | The synthetic nonapeptide reproduced the properties of the original DSIP isolate. 1 |
| Schneider-Helmert insomnia series | Humans, small series of chronic insomniacs, intravenous DSIP | Sleep was reported to normalize in most patients with follow-up of several months, in an uncontrolled design. 2 |
| Chronic pain pilot | Humans, small pilot series, chronic pain | Pain scores fell in most patients after a short intravenous course; no control group. 3 |
| Bes 1992 double-blind trial | Humans, n=16, randomized double-blind placebo-controlled, chronic insomnia | Small improvements in sleep efficiency and latency that the authors themselves called weak. 6 |
Safety
The old intravenous studies did not report adverse effects, but they were small and brief. The injectable DSIP sold online is unregulated, so purity and sterility are unverified, and there is no safety data for repeated subcutaneous use. Interactions with sedatives and effects in people with sleep apnea or psychiatric illness have not been studied. 267
Questions for your clinician
- Is there any controlled human trial for the use I have in mind, such as sleep?
- How would I know the purity and sterility of an injectable sold online?
- How could it interact with my sleep medicines or conditions?
Questions people ask
Is DSIP FDA-approved?
No. It has no approved use in the US or elsewhere. In July 2026 an FDA advisory panel voted against allowing pharmacies to compound it, citing the lack of adequate clinical data. 7
Does DSIP help you sleep?
The evidence is thin. Small studies from the 1980s reported better sleep in insomniacs, and a 16-person double-blind trial in 1992 found a weak effect the authors did not consider convincing. No larger or more recent trial exists. 26
Citations
- Schoenenberger 1977, Experientia: comparative properties of the original and synthetic DSIP nonapeptide pubmed.ncbi.nlm.nih.gov
- Schneider-Helmert 1981: synthetic DSIP in disturbed human sleep (DOI record) doi.org
- Neuropsychobiology: DSIP in chronic pain (DOI record) doi.org
- Neuropsychobiology: DSIP in withdrawal states (DOI record) doi.org
- JAAOS Global Research & Reviews 2025: review of peptides in orthopaedic practice doi.org
- Bes 1992, Neuropsychobiology: double-blind trial of DSIP in chronic insomnia pubmed.ncbi.nlm.nih.gov
- RAPS 2026: FDA advisory committee backs two more peptides, rejects one (emideltide/DSIP) for compounding list raps.org